Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment
Human Immunodeficiency Virus, Ischemic Heart Disease

About this trial
This is an interventional treatment trial for Human Immunodeficiency Virus focused on measuring Human immunodeficiency Virus (HIV), Highly Active Antiviral Therapy (HAART), Ischemic Heart Disease, OMACOR, Triglycerides, Endothelial function, Treatment Experienced
Eligibility Criteria
Inclusion Criteria: Man/women > 18 years of age Documented HIV infection On active treatment with HAART for at least 3 months. Written informed consent. This implies that the patient can read and understand Danish or English Exclusion Criteria: Age < 18 years Malign disease Patients assessed as not cooperative Patients planning to be pregnant or who are already pregnant or breast feeding. Patients who have been taking fish oil capsules prior to randomization. However, patients who have discontinued fish oil supplements at least 8 weeks prior to the first visit will be included Patients allergic to fish proteins Statin treatment that has been ongoing for less than three months, or a change in statin treatment dose within the last three months
Sites / Locations
- Aalborg Hospital, Department of Nephrology
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
1
2
Omacor 1000mg x 4 / day